OTCMKTS:ELOXD Eloxx Pharmaceuticals (ELOXD) Stock Price, News & Analysis $6.20 0.00 (0.00%) As of 09/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsSEC Filings About Eloxx Pharmaceuticals Stock (OTCMKTS:ELOXD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eloxx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$6.20▼$6.2050-Day Range$6.20▼$6.2052-Week Range$0.00▼$10.00VolumeN/AAverage Volume3,320 shsMarket Capitalization$2.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eloxx Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases caused by nonsense mutations. Its research centered on ribosome modulation technology, which was designed to encourage the cellular machinery to read through premature stop signals in genetic instructions and restore production of functional proteins. The company’s lead investigational product, ELX-02, was a synthetic aminoglycoside developed for potential use in diseases including cystic fibrosis and cystinosis. Eloxx also worked on ZKN-013, an orally administered small-molecule therapy intended to address nonsense-mutation disorders. These programs were investigational and had not received broad regulatory approval. Eloxx conducted development activities through clinical and research programs in the United States and other international markets. The company subsequently encountered financial difficulties and pursued restructuring and bankruptcy-related proceedings, after which its operations were substantially reduced. The company’s historical securities have traded over-the-counter under the symbol ELOXD.AI Generated. May Contain Errors. Read More Receive ELOXD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELOXD Stock News HeadlinesLeerink Partners Initiates Eloxx Pharmaceuticals With Outperform Rating, $32 PTSeptember 18, 2026 | marketscreener.comMEloxx Pharmaceuticals, Inc.: Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 12, 2026 | finanznachrichten.deWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the dot-com era split Pets.com from Amazon. One robotics business tied to his research posted $100 million in quarterly revenue, a fifth straight quarter of sequential growth, and 33.4% year-over-year growth. Meanwhile, three hyped names on his avoid list still depend on story over substance. See the full breakdown in his Great AI Shock briefing.September 24 at 1:00 AM | The Oxford Club (Ad)Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to NasdaqJune 8, 2026 | prnewswire.comEloxx Pharmaceuticals Inc.May 24, 2026 | barrons.comEloxx Pharmaceuticals Inc. (ELOX) SEC FilingsMay 21, 2026 | nasdaq.comEloxx Pharmaceuticals Delays Form 10-Q FilingAugust 15, 2025 | msn.comEloxx Pharmaceuticals Announces Key Corporate AccomplishmentsNovember 12, 2024 | tmcnet.comSee More Headlines ELOXD Stock Analysis - Frequently Asked Questions How have ELOXD shares performed this year? Eloxx Pharmaceuticals' stock was trading at $0.0011 at the beginning of the year. Since then, ELOXD shares have increased by 563,536.4% and is now trading at $6.20. How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals, Inc. (OTCMKTS:ELOXD) issued its quarterly earnings data on Monday, April, 3rd. The company reported ($32.12) EPS for the quarter, topping the consensus estimate of ($32.67) by $0.55. When did Eloxx Pharmaceuticals' stock split? Eloxx Pharmaceuticals shares reverse split on the morning of Monday, June 1st 2026.The 1-11 reverse split was announced on Monday, June 1st 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOXD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eloxx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eloxx Pharmaceuticals investors own include Tesla (TSLA), ADMA Biologics (ADMA), Adverum Biotechnologies (ADVM), Assertio (ASRT), Fulcrum Therapeutics (FULC), Akebia Therapeutics (AKBA). Company Calendar Last Earnings4/03/2023Today9/23/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ELOXD Previous SymbolNASDAQ:ELOX CIK1035354 Webwww.eloxxpharma.com Phone(781) 577-5300Fax908-864-4440Employees10Year Founded2013Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual Sales$6.36 million Price / Sales0.45 Cash FlowN/A Price / Cash FlowN/A Book Value($85.17) per share Price / Book-0.07Miscellaneous Outstanding Shares461,000Free Float342,000Market Cap$2.86 million OptionableNot Optionable Beta-1,932.72 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:ELOXD) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELOXD Stock Alerts